Genetic Signatures Ltd. (GSS) AI Stock Analysis

• Market Cap: AU$60.19M
• Dividend Yield: N/A
• Average Volume (3M): 151.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: 62.81%
• EPS Growth: 16.37%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.02
• Shares Outstanding: 227,138,820
• 10 Day Avg. Volume: 181,737
• 30 Day Avg. Volume: 151,854
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.53
• Price Target Upside: 103.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 41 Neutral
• Price Target: AU$0.50 ▲(92.31% Upside)

Genetic Signatures Ltd. faces significant financial and valuation challenges, with ongoing profitability and cash flow issues being the most critical factors. The technical analysis suggests a bearish trend, though there may be potential for a reversal. The lack of earnings call data and corporate events means these factors do not influence the score.

Genetic Signatures Ltd. Business Overview & Revenue Model

Company Description

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.

How the Company Makes Money

Genetic Signatures Ltd. generates revenue through the sale of its diagnostic tests and related products to laboratories and healthcare providers. The company employs a direct sales model as well as partnerships with distributors to reach a wider market. Key revenue streams come from the sales of its assays, which are used for pathogen detection in clinical diagnostics. Additionally, GSS may earn revenue through licensing agreements or collaborations with other companies in the healthcare and biotechnology sectors, enhancing its market presence and product offerings. The company’s growth is also supported by ongoing developments in molecular diagnostics and increased demand for rapid testing solutions.

Genetic Signatures Ltd. Financial Statement Overview

Summary

Genetic Signatures Ltd. faces significant financial challenges, particularly in profitability and cash flow generation. Despite a strong equity base and low leverage, the company's inability to generate positive earnings and cash flow poses risks to its financial stability. Recent revenue growth is a positive sign, but sustained improvement in profitability and cash flow is crucial for long-term success.

Income Statement

Genetic Signatures Ltd. has experienced fluctuating revenue growth, with a recent positive trend of 8.45% in the latest year. However, profitability remains a significant concern, as indicated by negative net profit margins and EBIT margins over the past years. The company has struggled to maintain positive gross profit margins, and the consistent negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with a low debt-to-equity ratio of 0.0158, indicating minimal leverage. However, the return on equity is negative, reflecting the company's inability to generate profits from its equity base. The equity ratio remains stable, suggesting a solid capital structure despite profitability issues.

Cash Flow

Cash flow analysis reveals a challenging situation, with negative operating and free cash flows. Although there is a slight improvement in free cash flow growth, the operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is above 1, suggesting that free cash flow is relatively better than net income, but overall cash generation remains weak.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	15.90M	15.90M	9.77M	16.94M	35.42M	28.28M
Gross Profit	-2.39M	7.78M	4.31M	-12.74M	7.21M	4.27M
EBITDA	-15.87M	-16.08M	-19.82M	-13.14M	4.70M	3.22M
Net Income	-20.10M	-20.10M	-17.86M	-14.05M	3.06M	1.76M
Balance Sheet
Total Assets	54.63M	54.63M	67.29M	49.08M	59.65M	54.05M
Cash, Cash Equivalents and Short-Term Investments	31.30M	31.30M	36.25M	16.35M	36.90M	30.12M
Total Debt	791.00K	791.00K	1.22M	0.00	34.00K	399.00K
Total Liabilities	4.54M	4.54M	6.18M	6.16M	4.85M	4.71M
Stockholders Equity	50.09M	50.09M	61.10M	42.91M	54.80M	49.34M
Cash Flow
Free Cash Flow	-12.94M	-13.19M	-14.91M	-20.55M	6.82M	-784.00K
Operating Cash Flow	-12.29M	-12.29M	-10.12M	-12.45M	9.81M	4.20M
Investing Cash Flow	-24.30M	-24.30M	-4.79M	-8.09M	-2.99M	-4.98M
Financing Cash Flow	7.79M	7.79M	34.81M	-23.00K	-101.00K	-190.00K

Genetic Signatures Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.32, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 33.85 is Neutral, neither overbought nor oversold. The STOCH value of 5.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GSS.

Genetic Signatures Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	66 Neutral	41.98M	22.28	78.86%	8.14%	11.93%	2.39%
LDX	55 Neutral	133.60M	-11.49	0.00%	―	12.96%	45.59%
IIQ	49 Neutral	42.42M	-6.42	0.00%	―	2.33%	12.50%
RHY	45 Neutral	30.28M	-7.29	0.00%	―	0.00%	56.42%
BDX	43 Neutral	23.79M	-3.48	0.00%	―	0.00%	23.85%
GSS	41 Neutral	AU$60.19M	―	-36.16%	―	62.81%	16.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Genetic Signatures Ltd. Corporate Events

Genetic Signatures Ltd. Releases 2025 Corporate Governance Statement

Genetic Signatures Ltd. has released its corporate governance statement for the financial year ending June 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability. This announcement reinforces the company’s dedication to maintaining high governance standards, potentially strengthening stakeholder confidence and enhancing its industry reputation.

The most recent analyst rating on (AU:GSS) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.

Genetic Signatures Achieves Revenue Growth and Strategic Transformation in FY25

Genetic Signatures Ltd. reported a transformative year with a 63% increase in revenue to $15.9 million, driven by strong respiratory sales in Australia. The company reduced its underlying loss by 28% to $12.7 million, despite a statutory loss of $20.1 million due to a $7.0 million impairment. Strategic partnerships with Tecan Group and Repado aim to launch a next-generation automated solution, while the first US commercial contract marks a significant market entry. The company is focusing on core business pillars, streamlining its product portfolio, and enhancing automation, positioning itself for sustainable growth and innovation in molecular diagnostics.

The most recent analyst rating on (AU:GSS) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.

Genetic Signatures to Announce FY 25 Results and Host Investor Webinar

Genetic Signatures Ltd. announced it will release its FY 25 annual results on August 25, 2025, followed by an investor webinar hosted by CEO Allison Rossiter and CFO Karl Pechmann. This event is an opportunity for stakeholders to gain insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder engagement.

The most recent analyst rating on (AU:GSS) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.

Genetic Signatures Ltd Reports Stable Sales Amid Strategic Restructuring

Genetic Signatures Ltd reported quarterly sales of $4.4 million, maintaining levels from the previous year due to increased testing during the Australian winter respiratory season. The company implemented organizational changes, including restructuring its US leadership and team to align with strategic goals. Despite challenges in the US market, a new contract was secured post-quarter. The company is developing an automated, high-throughput solution through a strategic partnership and has engaged with global molecular experts to promote its diagnostic solutions. With a strong cash balance of $30.9 million, the company is focusing on aligning resources and managing expenses to support future growth.

The most recent analyst rating on (AU:GSS) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.

Genetic Signatures Partners with Tecan and Repado for Advanced Diagnostic Solutions

Genetic Signatures Ltd has announced a strategic partnership with Tecan and Repado to develop a fully automated, scalable diagnostic platform for infectious disease testing. This collaboration aims to enhance laboratory efficiency and compliance by integrating Tecan’s automation technology, Repado’s regulatory-compliant software, and Genetic Signatures’ assay portfolio. The initiative is expected to significantly improve testing processes and regulatory alignment, with early access planned for select global labs.

The most recent analyst rating on (AU:GSS) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.

Genetic Signatures Ltd. Announces Cessation of Securities

Genetic Signatures Ltd. announced the cessation of 240,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may affect the company’s capital structure and could have implications for its financial strategy and stakeholder interests.

The most recent analyst rating on (AU:GSS) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.

Genetic Signatures Ltd. Announces Change in Substantial Holder Interests

Genetic Signatures Ltd. has announced a change in the interests of a substantial holder, Regal Funds Management Pty Ltd and its associates, in the company’s voting securities. The change reflects an increase in voting power from 6.75% to 8.87%, indicating a significant shift in shareholder influence. This development could impact the company’s governance and strategic decisions, potentially affecting stakeholders and market dynamics.

The most recent analyst rating on (AU:GSS) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.